The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan

por Jhund, Pardeep S, McMurray, John J V
Publicado 2016

Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction

por Packer, Milton, McMurray, John J.V.
Publicado 2021

SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure

por Docherty, Kieran F., McMurray, John J.V.
Publicado 2020

Insights into foundational therapies for heart failure with reduced ejection fraction

por McMurray, John J. V., Docherty, Kieran F.
Publicado 2022

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?

por Kondo, Toru, Jhund, Pardeep S., McMurray, John J.V.
Publicado 2022

Who Benefits From a Defibrillator—Balancing the Risk of Sudden Versus Non-sudden Death

por Beggs, Simon A. S., Gardner, Roy S., McMurray, John J. V.
Publicado 2018

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction

por Dewan, Pooja, Docherty, Kieran F., McMurray, John J.V.
Publicado 2019

Talking to patients with heart failure about end of life

por Campbell, Ross T., Petrie, Mark C., McMurray, John J.V.
Publicado 2018

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context

por McMurray, John J V, Solomon, Scott D, Docherty, Kieran F, Jhund, Pardeep S
Publicado 2020

What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?

por Cannon, Jane A, McKean, Andrew R, Jhund, Pardeep S, McMurray, John J V
Publicado 2015

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

por Sattar, Naveed, McLaren, James, Kristensen, Søren L., Preiss, David, McMurray, John J.
Publicado 2016

Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

por Sattar, Naveed, McLaren, James, Kristensen, Søren L., Preiss, David, McMurray, John J.
Publicado 2016

Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it

por Ahmad, Faheem A., Petrie, Mark C., McMurray, John J.V., Lang, Ninian N.
Publicado 2019

Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence

por Lee, Matthew M. Y., Sattar, Naveed, McMurray, John J. V., Packard, Chris J.
Publicado 2019

Association is not causation: treatment effects cannot be estimated from observational data in heart failure

por Rush, Christopher J, Campbell, Ross T, Jhund, Pardeep S, Petrie, Mark C, McMurray, John J V
Publicado 2018

Aliskiren, ALTITUDE, and the implications for ATMOSPHERE

por McMurray, John J.V., Abraham, William T., Dickstein, Kenneth, Køber, Lars, Massie, Barry M., Krum, Henry
Publicado 2012

B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review

por Hawkins, Nathaniel M., Khosla, Amit, Virani, Sean A., McMurray, John J. V., FitzGerald, J Mark
Publicado 2017

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

por Vaduganathan, Muthiah, Vardeny, Orly, Michel, Thomas, McMurray, John J.V., Pfeffer, Marc A., Solomon, Scott D.
Publicado 2020

Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis

por Burnett, Heather, Earley, Amy, Voors, Adriaan A., Senni, Michele, McMurray, John J.V., Deschaseaux, Celine, Cope, Shannon
Publicado 2017

Physical Frailty and Use of Guideline‐Recommended Drugs in Patients With Heart Failure and Reduced Ejection Fraction

por Kondo, Toru, Adachi, Takuji, Kobayashi, Kiyonori, Okumura, Takahiro, Izawa, Hideo, Murohara, Toyoaki, McMurray, John J. V., Yamada, Sumio
Publicado 2023